Journal: The Journal of Clinical Endocrinology and Metabolism

Article Title: Potential Utility of Circulating MicroRNA-483 as a Biomarker for IGF-II–Associated Non–Islet Cell Tumor Hypoglycemia

doi: 10.1210/clinem/dgae879

Figure Lengend Snippet: Tissue expression levels of IGF2 mRNA, miR-483-5p, and miR-483-3p in IGF-II–producing solitary fibrous tumors. Expression levels of IGF2 mRNA (A), miR-483-5p (B), and miR-483-3p (C) in tumor tissues and the surrounding surgical margins from cases of confirmed NICTH due to solitary fibrous tumors that underwent surgery (n = 11). In these cases, big IGF-II was confirmed by Western blotting in the tumors, but not in the surrounding margins. The central horizontal solid line and the whiskers for each value represent the median and 25th/75th percentiles, respectively. Open circles represent surgical margins (Margin), and gray circles represent tumors (Tumor). *** P < .001. P values were determined using the Mann–Whitney U test.

Article Snippet: From the total RNA, IGF2 mRNA levels were also measured using SuperScript VILO cDNA Synthesis Kit (Thermo Fisher Scientific) and TaqMan Gene Expression Assays (Thermo Fisher Scientific) for IGF2 (Hs04188276_m1).

Techniques: Expressing, Western Blot, MANN-WHITNEY

Journal: Biomedicines

Article Title: Differential Expression of Long Non-Coding RNA IGF2-AS in Tamoxifen-Resistant Breast Cancer Cells

doi: 10.3390/biomedicines13092087

Figure Lengend Snippet: Expression of IGF2-AS in breast cancer cell lines and prognosis in the Kaplan–Meier (KM) plotter database. ( A ) Expression levels of IGF2-AS in various breast cell lines. Yellow bars represent mean IGF2-AS expression levels, and error bars indicate standard deviation (SD) from three independent experiments. ( B , C ) Upregulation of IGF2-AS in MCF7 and MDA-MB231 cell lines. ( D ) Overall prognosis based on IGF2-AS expression levels in breast cancer. ( E , F ) High IGF2-AS expression is associated with significantly poorer prognosis in hormone-positive breast cancers treated with endocrine therapy and in triple-negative breast cancers, according to the KM plotter database.

Article Snippet: TaqMan probes for IGF2-AS (Hs00212651_m1) and β-actin (Hs99999903_m1) were purchased from Thermo Fisher Scientific (Thermo Fisher Scientific, Waltham, MA, USA).

Techniques: Expressing, Standard Deviation

Journal: Biomedicines

Article Title: Differential Expression of Long Non-Coding RNA IGF2-AS in Tamoxifen-Resistant Breast Cancer Cells

doi: 10.3390/biomedicines13092087

Figure Lengend Snippet: Expression profile of various lncRNAs in tamoxifen-resistant breast cancer cell lines (TAMR-V and TAMR-H) compared to conventional MCF7 cells. IGF2-AS (yellow bar) expression was notably higher in both TAMR cell lines.

Article Snippet: TaqMan probes for IGF2-AS (Hs00212651_m1) and β-actin (Hs99999903_m1) were purchased from Thermo Fisher Scientific (Thermo Fisher Scientific, Waltham, MA, USA).

Techniques: Expressing

Journal: Biomedicines

Article Title: Differential Expression of Long Non-Coding RNA IGF2-AS in Tamoxifen-Resistant Breast Cancer Cells

doi: 10.3390/biomedicines13092087

Figure Lengend Snippet: Impact of IGF2-AS knockdown on cell viability in tamoxifen-resistant (TAMR) breast cancer cell lines. Error bars indicate standard deviation (SD) from three independent experiments. ( A , C ) Confirmation of IGF2-AS knockdown in TAMR cell lines. Both TAMR breast cancer cell lines were treated with si-IGF2-AS for 48 h, and qRT-PCR was used to analyze IGF2-AS expression. ( B , D ) TAMR breast cancer cell lines were treated with si-IGF2-AS for 48 h; cell viability was measured by MTT assay.

Article Snippet: TaqMan probes for IGF2-AS (Hs00212651_m1) and β-actin (Hs99999903_m1) were purchased from Thermo Fisher Scientific (Thermo Fisher Scientific, Waltham, MA, USA).

Techniques: Knockdown, Standard Deviation, Quantitative RT-PCR, Expressing, MTT Assay

Journal: Biomedicines

Article Title: Differential Expression of Long Non-Coding RNA IGF2-AS in Tamoxifen-Resistant Breast Cancer Cells

doi: 10.3390/biomedicines13092087

Figure Lengend Snippet: Impact of IGF2-AS knockdown on cell invasion in tamoxifen-resistant (TAMR) breast cancer cell lines. Error bars indicate standard deviation (SD) from three independent experiments. Transwell invasion assay with TAMR-V ( A ) and TAMR-H cell lines ( B ). TAMR breast cancer cell lines were transfected with control siRNA and si-IGF2-AS for 24 h. The transfected cells were harvested and seeded in a Matrigel-coated transwell. After 48 h, the number of invading cells was assessed. The microscope magnification was 200×.

Article Snippet: TaqMan probes for IGF2-AS (Hs00212651_m1) and β-actin (Hs99999903_m1) were purchased from Thermo Fisher Scientific (Thermo Fisher Scientific, Waltham, MA, USA).

Techniques: Knockdown, Standard Deviation, Transwell Invasion Assay, Transfection, Control, Microscopy

Journal: Biomedicines

Article Title: Differential Expression of Long Non-Coding RNA IGF2-AS in Tamoxifen-Resistant Breast Cancer Cells

doi: 10.3390/biomedicines13092087

Figure Lengend Snippet: Impact of IGF2-AS knockdown on cell migration in tamoxifen-resistant (TAMR) breast cancer cell lines and the wound healing assay with TAMR-V ( A ) and TAMR-H cell lines ( B ). si-IGF2AS- or control siRNA-transfected TAMR breast cancer cell lines were scratched with a pipette tip, and wound images were captured at 0, 48, and 72 h. The wound area was measured by the ImageJ wound healing tool. Error bars indicate standard deviation (SD) from three independent experiments, and red lines are borderline between cells and scratched wound, which is placed to show clear wound area. The microscope magnification was 40×.

Article Snippet: TaqMan probes for IGF2-AS (Hs00212651_m1) and β-actin (Hs99999903_m1) were purchased from Thermo Fisher Scientific (Thermo Fisher Scientific, Waltham, MA, USA).

Techniques: Knockdown, Migration, Wound Healing Assay, Control, Transfection, Transferring, Standard Deviation, Microscopy

Journal: Biomedicines

Article Title: Differential Expression of Long Non-Coding RNA IGF2-AS in Tamoxifen-Resistant Breast Cancer Cells

doi: 10.3390/biomedicines13092087

Figure Lengend Snippet: LncRNA IGF2-AS expression was significantly higher in patients with tamoxifen-resistant (TAMR) breast cancer compared to patients with other subtypes. ( A ) The boxplot of gene expression of IGF2-AS compared to GAPDH expression in patients with luminal subtype ( n = 8), HER2 subtype ( n = 2), triple-negative subtype ( n = 8), and TAMR patients ( n = 4). Error bars indicate standard deviation (SD) from three independent experiments. ( B ) Mean value of IGF2-AS expression in luminal type and TAMR breast cancers and the difference in mean values. The dot lines indicate the average value of each type and error bar indicate margin of error for the average value.

Article Snippet: TaqMan probes for IGF2-AS (Hs00212651_m1) and β-actin (Hs99999903_m1) were purchased from Thermo Fisher Scientific (Thermo Fisher Scientific, Waltham, MA, USA).

Techniques: Expressing, Gene Expression, Standard Deviation